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Introduction 
Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 
eosinophilic polyangiitis (EGPA) are the antineutrophil cytoplasmic antibody (ANCA) 
associated vasculitides (AAV). They are rare autoimmune conditions characterised by 
inflammation and sometimes necrosis of blood vessels unified by their association 
with antibody production towards antigens in the neutrophil cytoplasm. The two 
antigens of interest are proteinase 3 (PR3) and myeloperoxidase (MPO). 
This review examines the evidence of the current state of play in the care of patients 
with this condition.  
Standards of care 
1. Early diagnosis and treatment 
There are no diagnostic criteria for the diagnosis of AAV, there are no 
diagnostic tests for AAV, and there are no pathognomonic signs for AAV. But 
like all complex and life-threatening conditions, early diagnosis and treatment 
must be a goal. We know that damage is accrued over time and increasing 
damage has adverse prognosis.(1) 
a. Pattern recognition – Pattern recognition is still the key to making an 
early diagnosis of AAV.(2) Eosinophilia in asthma, urine analysis in 
patients with persistent upper respiratory symptoms, the presence of 
multiple system involvement should all lead to increased suspicion of 
AAV. We know that GPA is a spectral disorder much like leprosy, 
ranging from the indolent granulomatous pattern of involvement to 
acute life-threatening vasculitis.(3) Early diagnosis due to 
otorhinolaryngological involvement may be the reason for a more 
favourable prognosis in this group of patients.(4, 5) Conversely, when 
these ‘herald’ symptoms are not present, as in MPA, there is a greater 
chance of sclerosis being present on the renal biopsy.(6)  
b. Getting the name right – It was not that long ago that all patients with 
MPA and CSS were grouped together with polyarteritis nodosa.(7) The 
American College of Rheumatology classified the various systemic 
vasculitides in 1990 but ignored microscopic polyangiitis.(8, 9) Two 
international consensus conferences have influenced on our practice 
on naming the distinct vasculitides.(10, 11) It is also recognised that 
these are not diagnostic criteria, and their use as diagnostic criteria is 
met with disappointing results.(12, 13) The authors use the European 
Medicines Agency algorithm to classify vasculitis in clinical practice.(14) 
Usually the reason for getting the name right is to inform treatment 
and prognosis. It could be argued, that in AAV the treatment is led by 
the level of organ involvement irrespective of the name provided to the 
condition.(15, 16) But the prognosis is related to the disease 
classification.(17, 18) On the flip-side, it could be argued that the 
prognosis may be related more to the clinical phenotype of the disease 
and therefore the names of the conditions as they currently stand may 
need revision in the future. For example, a recent review of five clinical 
trials identified the following clinicopathological subtypes - renal AAV 
with PR3-ANCA (40%), renal AAV without PR3-ANCA (32%), non-renal 
AAV' (12%), cardiovascular AAV' (9%), and gastrointestinal AAV' 
(7%).(19) The five clusters had distinct death and relapse rates. It is 
desirable to validate any international consensus criteria in local 
population to improve acceptance and robustness of concepts that 
have often been formulated in populations which are genetically and 
environmentally very different.(20)  
c. Context of laboratory investigations – From the experience of the 
authors, the internist is still guided by the presence of absence of ANCA 
to make a diagnosis of AAV. We know that in the appropriate clinical 
context, the presence of either PR3-ANCA or MPO-ANCA is highly 
specific for a diagnosis of small vessel vasculitis.(21) We also know that 
active GPA/MPA is associated with PR3/MPO ANCA positivity in about 
90% of patients.(22) But ANCA are commonly generated by infections. 
In the Indian scenario, it is very relevant that multi-system diseases like 
malaria, tuberculosis and leprosy have been known to generate 
ANCA.(23) In one study of 70 consecutive patients with tuberculosis, 
30% were ANCA positive and >75% of these demonstrated either 
PR3/MPO-ANCA.(24) ANCA cannot be used for diagnosis of AAV, but 
remain helpful in the appropriate clinical context. 
Histopathology remains the gold standard of diagnosis. It may not 
always be needed, and it may not always be possible. The results 
depend on the biopsied organ (lower yield from nasal biopsy than renal 
biopsy), the skill of the operator and the skill of the pathologist. If there 
is any doubt about the diagnosis, a histological diagnosis remains the 
standard of care. 
d. Specialist input – AAV are rare conditions with an annual incidence of 
10-20/million.(25, 26) The British and European societies recommend 
that these rare and complex patients should be treated at or in 
consultation with specialist centres.(15, 16) A Medline search for 
literature from India using the search string "Anti-Neutrophil 
Cytoplasmic Antibody-Associated Vasculitis"[Mesh] NOT "Case 
reports"[pt] AND "India"[all fields] provides 6 papers published in the 
last 5 years (search as of 31/07/2015). During the same time there were 
116 papers from the UK. This may suggest that there is a dearth of 
academic centres and physicians caring for patients with AAV. 
Specialist input cannot be provided without adequate number of 
specialists. 
 
2. Standardized evaluation of patients with systemic vasculitis 
In the absence of biomarkers, standardized evaluation of patients with AAV 
using clinical activity tools is recommended for documenting the full extent of 
the disease and for identifying new or resolving clinical signs on follow up. The 
Birmingham Vasculitis Activity Score (BVAS) v3 or the BVAS/WG are most 
commonly used for this purpose.(27, 28) In the author’s experience, the use of 
these tools in routine clinical practice has the following advantages – 
a. Identifying sub-clinical disease activity in organs other than the 
presenting manifestations allowing for recognition of disease extent 
and differential diagnosis. For example, a 67 year old woman 
presenting with headache, raised inflammatory markers and 
monocular loss of vision was considered to have giant cell arteritis till 
the use of BVAS v3 in clinic identified an old nasal septal perforation 
leading to further investigations and a diagnosis of GPA. She was MPO-
ANCA positive with MRI evidence of meningitis at the orbital apex and 
cavernous sinus. 
b. Identifying new disease in hitherto unaffected systems on follow up. 
(29) 
c. Quantifying the disease activity with a numerical score which can be 
used to evaluate the course of the disease. 
d. Teaching the user the common and serious manifestations of vasculitis. 
 
3. Standards for choice of drugs 
a. Remission Induction – Combination therapy with cyclophosphamide 
and prednisolone made survival an achievable outcome.(30) However, 
relapses and iatrogenic side effects were common.(31) This changed 
the drive in the research agenda to limit the exposure of 
cyclophosphamide. Remission induction with pulsed intravenous 
cyclophosphamide remains the standard of treatment. The regimen 
devised by the European Vasculitis Society is 15 mg/kg/pulse (max 
1.2g) every 2 weeks for the first 3 pulses and then 3 weekly for the next 
3 pulses. In a randomized controlled trial of 149 patients with 
GPA/MPA, comparing this pulsed regimen with daily oral 
cyclophosphamide 2 mg/kg/day, there was no difference in time to 
remission in both arms (median of 3 months).(32) The daily oral arm 
had nearly twice the cumulative cyclophosphamide dose (15.9g vs. 
8.2g) and consequently higher hazard of leucopenia. Longer follow-up 
of this cohort (4.3 years) demonstrated that the pulsed 
cyclophosphamide group suffered significantly greater relapse rates 
(40% vs. 21%) but this did not affect mortality.(33) The authors still 
believe that pulsed cyclophosphamide remains the standard of therapy 
due to lower cumulative dose of cyclophosphamide. 
Rituximab 375 mg/m2/week for 4 weeks is non-inferior to pulsed 
cyclophosphamide in producing remission in GPA/MPA.(34) The risk of 
adverse events is the same with both drugs implying that pulsed 
cyclophosphamide is not particularly toxic and that most of the 
therapy-related toxicity may be related to the use of glucocorticoids. In 
patients with relapsing disease, rituximab has been shown to be 
superior to cyclophosphamide.(34) Rituximab has become the new 
standard of therapy for remission induction in patients with relapsing 
disease and those who have a contraindication to cyclophosphamide, 
e.g. young women of child-bearing age, patients with urothelial 
cancers. 
In a RCT of 100 patients, methotrexate 20-25 mg/week was non-
inferior to cyclophosphamide 2 mg/kg/day in inducing remission.(35) 
But long-term follow up of these patients (median 6 years) showed that 
patients treated with methotrexate were more likely to relapse and 
needed more glucocorticoid therapy.(36) The authors do not use this 
anymore except in patients with non-organ threatening disease with 
contraindication to cyclophosphamide who have no evidence of organ 
dysfunction. Nasal bony destruction and olfactory dysfunction should 
not be considered as non-organ threatening disease for this purpose.  
Mycophenolate mofetil 1-1.5 g/day can be considered in non-organ 
threatening AAV if there is a contraindication to methotrexate, 
cyclophosphamide or rituximab. (37) 
EULAR and BSR guidance recommends use of plasma exchange in 
rapidly progressive severe renal disease (creatinine > 500 µmol/litre) 
(18). Use of Plasma Exchange could be considered in patients with 
severe renal disease or rapidly progressive renal failure as an adjunct 
to cyclophosphamide.(38) 
Glucocorticoid therapy is an important adjunct to chemotherapy or 
immunotherapy. In patients with life-threatening or organ-threatening 
disease, it is common practice to use pulsed intravenous 
methylprednisolone 1 g every day for 3 days. Subsequently, oral 
prednisolone 1 mg/kg/day tapered to about 10-15 mg/day at 3 months 
is advocated. In recent years, there has been increasing recognition of 
the toxicity of prednisolone and this will hopefully lead to the 
development of prednisolone-light regimens. 
 
b. Remission Maintenance – The long-term toxicity of cyclophosphamide 
provoked the search for alternative agents to maintain remission.(31) 
Azathioprine (2mg/kg/day) is well established as an effective agent for 
use as maintenance therapy after remission induction. In a RCT of 155 
patients with AAV, azathioprine (2 mg/kg/day) was shown to be as 
effective as cyclophosphamide (1.5 mg/kg/day) for maintaining 
remission up to 18 months, but more safely.(39) It remains the 
standard of remission maintenance. 
In those patients who have had methotrexate used for remission 
induction, there is evidence for its continuing use to maintain 
remission. In a RCT involving 126 patients with GPA/MPA, 
methotrexate 25 mg/week was no more toxic than azathioprine 2 
mg/kg/day.(40) 
Rituximab in varying doses have been used to maintain remission in 
AAV. In one RCT, it has been shown to be superior to azathioprine.(41) 
In the UK, rituximab (1 g pulse every 6 months for 2 years – then 
observe) is recommended for maintaining remission in patients with 
refractory disease post-cyclophosphamide or relapsing disease post-
rituximab. A clinical trial examining its efficacy against standard 
maintenance of azathioprine 2 mg/kg/day is underway and may 
become the new standard of therapy. 
Currently, all patients must continue immunosuppression for at least 2 
years. Patients with persistent PR3-ANCA may need longer 
immunosuppression. 
Prednisolone is commonly used as an adjunct. Every effort should be 
made to get patients off glucocorticoid therapy. Relapses should not be 
treated with just prednisolone increments, but should be accompanied 
with a change in the chemotherapy/immunotherapy as well. 
 
4. Recognition and management of co-morbidities 
a. Infections – Infection is the main cause of early mortality in patients 
with AAV.(18) Prophylaxis against Pneumocystis jirovecii is commonly 
provided with trimethoprim/sulfamethoxazole (800/160 mg three 
times a week) for the duration of cyclophosphamide treatment. In 
patients who cannot tolerate this drug, we do not regularly administer 
pentamidine. Blood count monitoring, education of patients to seek 
early help for infection related symptoms and open access to a 
vasculitis unit may help minimise the mortality in this group of patients. 
b. Cardiovascular risk – Patients with AAV are at a higher risk of 
cardiovascular events and hypertension than the general 
population.(42) While it is imperative to address the traditional 
Framingham risk factors, control of blood pressure, especially in MPO-
ANCA positive patients is important.(43) 
c. Urothelial risk – Cyclophosphamide is associated with urothelial 
cancers and bladder injury.(44) It should be a standard of care to refer 
patients for a cystoscopy if there is persistent non-glomerular dipstick 
haematuria. 
d. Monitoring damage – Diabetes mellitus, osteoporosis and other long-
term risks of glucocorticoid use should be screened for on a regular 
basis. 
 
5. Patient education – Patients with AAV want information about their health, 
prognosis and therapy. They prefer to get their information from health-care 
professionals who deal with vasculitis as opposed to from patient support 
groups.(45) But, it is important to develop different kinds of educational 
material so that they can take things away and digest the information in their 
own time.(46) 
Discussion 
Over the past 25 years, collaborative clinical trials in vasculitis have changed the face 
of vasculitis therapeutics. Patients with vasculitis have a reasonable expectation of 
surviving a decade after diagnosis and leading a meaningful and economically 
productive life. With greater evidence there has been an evolution of clinical 
standards. But, as with everything else, the evolution of standards has not been 
uniform across the globe. Like-minded vasculitis clinicians have driven the formation 
of the European Vasculitis Society and the Vasculitis Clinical Research Consortium in 
Europe and USA respectively. Several clinicians in other parts of the world have 
participated in the collaborative clinical trials, but these remain predominantly 
European and North American initiatives. 
Over the past 5 years, rituximab has become the standard of care for remission 
induction in young women, relapsing patients and those with urothelial cancers. The 
availability of this expensive drug has led to initiatives in the UK to recognise specialist 
centres which can supervise the use of this drug but more importantly advice on the 
care of the patients who need this drug. Methotrexate is falling out of favour. In 
clinical trial as well as in personal experience, it did not fulfil its early promise and we 
fear the same for mycophenolate mofetil – but time will tell! 
Using a piece of paper – BVAS v3 or BVAS/WG seems to be an archaic way of assessing 
disease activity, but for those of us who do it regularly, it is proving invaluable. It is a 
simple but effective way of making sure that all activity is accounted for and forces 
the clinician to make a judgement on every symptom and its relationship to the 
disease – activity, damage or coincidental. It needs training for its use to ensure that 
it is used appropriately. 
We are making people live longer with complex drug regimens. This is now allowing 
us to see the havoc that the disease and its treatment can sometimes cause the body. 
It should not be a surprise that patients with a vascular problem have greater risk of 
cardiovascular complications, especially when we use high-dose glucocorticoids to 
treat it. We need to be more vigilant about monitoring those patients when remission 
has been achieved. 
EGPA has become an orphan amongst orphans. There is very little data to say anything 
meaningful about this disease. Most of what we have said above is based on data from 
GPA and MPA. It is time that the vasculitis community brought this condition into 
focus. 
The remit of this paper was to address the need for a change in standards of care for 
AAV. The short answer to that question would be ‘yes’. There is always need to change 
and evolve with increasing availability of evidence and we anticipate that this will 
continue to evolve rapidly – get on board and enjoy the ride. 
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